Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes
This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We col...
Gespeichert in:
| Veröffentlicht in: | The European journal of health economics 2010-06, Vol.11 (3), p.279-290 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 290 |
|---|---|
| container_issue | 3 |
| container_start_page | 279 |
| container_title | The European journal of health economics |
| container_volume | 11 |
| creator | Tsai, Yi-Wen Wen, Yu-Wen Huang, Weng-Foung Kuo, Ken N. Chen, Pei-Fen Shih, Hsin-Wei Lee, Yue-Chune |
| description | This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospitallevel pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl-Hirschman indices. We found a negative association (coefficient = — 0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of Pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs. |
| doi_str_mv | 10.1007/s10198-009-0174-1 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_733565317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40730762</jstor_id><sourcerecordid>40730762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-cd5326684b6c2643b49aa515ea149be99e715f62cffdd89f2d62a0dbefba86303</originalsourceid><addsrcrecordid>eNp9kc1uFSEYhifGxtbqBbjQEDddTeVngMFd01g1aVIXdU0Y-KaH4xwYgbHR6_CCpZlTrS5cQeB5n4_wNs0Lgk8JxvJNJpiovsVYtZjIriWPmiMiSN9Kgcnj-z1X_WHzNOctxpRKyp40h0SJTgkhjpqfnzYm7YyFpXhrJjRDgJJM8TGgOKIAt8il5QaZ4ND8N7oz6QsUlEtabFkSIB_QtfG3JrxFm5hnX8zUTvANqjVBtsnP99qy8eZHnLzzAVw9g4zGmJDzZoAC-VlzMJopw_P9etx8vnh3ff6hvbx6__H87LK1HeeltY4zKkTfDcJS0bGhU8ZwwsGQTg2gFEjCR0HtODrXq5E6QQ12A4yD6QXD7Lg5Wb1zil8XyEXvfLYwTSZAXLKWjHHBGZGVfP0PuY1LCvVxmiimiBScVoiskE0x5wSjnpOvv_RdE6zvCtNrYboWpu8K06RmXu3Fy7AD9yexb6gCdAVyvQo3kB5M_o_15Rra5hLTb2mHJcNSUPYL1E6uXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>193917652</pqid></control><display><type>article</type><title>Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>SpringerLink Journals - AutoHoldings</source><creator>Tsai, Yi-Wen ; Wen, Yu-Wen ; Huang, Weng-Foung ; Kuo, Ken N. ; Chen, Pei-Fen ; Shih, Hsin-Wei ; Lee, Yue-Chune</creator><creatorcontrib>Tsai, Yi-Wen ; Wen, Yu-Wen ; Huang, Weng-Foung ; Kuo, Ken N. ; Chen, Pei-Fen ; Shih, Hsin-Wei ; Lee, Yue-Chune</creatorcontrib><description>This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospitallevel pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl-Hirschman indices. We found a negative association (coefficient = — 0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of Pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs.</description><identifier>ISSN: 1618-7598</identifier><identifier>EISSN: 1618-7601</identifier><identifier>DOI: 10.1007/s10198-009-0174-1</identifier><identifier>PMID: 19649666</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer</publisher><subject>Bargaining ; Brand names ; Databases, Factual ; Diabetes ; Diabetes Mellitus - drug therapy ; Drug Industry ; Drug prescriptions ; Drug prices ; Economic Competition ; Economic Policy ; FDA approval ; Generic drugs ; Health care expenditures ; Health Care Management ; Health Economics ; Health insurance ; Herfindahl Hirschman index ; Hospital costs ; Hospitals ; Hospitals - classification ; Hospitals - statistics & numerical data ; Humans ; International comparisons ; Market prices ; Market shares ; Marketing of Health Services ; Medical technology ; Medicine ; Medicine & Public Health ; National health insurance ; National Health Programs - statistics & numerical data ; Nonprofit hospitals ; Original Paper ; Pharmaceutical industry ; Pharmaceutical preparations ; Pharmaceutical Preparations - economics ; Pharmaceuticals ; Pharmacoeconomics and Health Outcomes ; Practice Patterns, Physicians' - statistics & numerical data ; Prescription drugs ; Price level changes ; Public Finance ; Public Health ; Reimbursement ; Studies ; Taiwan ; Technological change ; Thiazolidinediones - economics ; Thiazolidinediones - therapeutic use</subject><ispartof>The European journal of health economics, 2010-06, Vol.11 (3), p.279-290</ispartof><rights>2010 Springer-Verlag Berlin Heidelberg</rights><rights>Springer-Verlag 2009</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-cd5326684b6c2643b49aa515ea149be99e715f62cffdd89f2d62a0dbefba86303</citedby><cites>FETCH-LOGICAL-c455t-cd5326684b6c2643b49aa515ea149be99e715f62cffdd89f2d62a0dbefba86303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40730762$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40730762$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,41488,42557,51319,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19649666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsai, Yi-Wen</creatorcontrib><creatorcontrib>Wen, Yu-Wen</creatorcontrib><creatorcontrib>Huang, Weng-Foung</creatorcontrib><creatorcontrib>Kuo, Ken N.</creatorcontrib><creatorcontrib>Chen, Pei-Fen</creatorcontrib><creatorcontrib>Shih, Hsin-Wei</creatorcontrib><creatorcontrib>Lee, Yue-Chune</creatorcontrib><title>Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes</title><title>The European journal of health economics</title><addtitle>Eur J Health Econ</addtitle><addtitle>Eur J Health Econ</addtitle><description>This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospitallevel pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl-Hirschman indices. We found a negative association (coefficient = — 0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of Pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs.</description><subject>Bargaining</subject><subject>Brand names</subject><subject>Databases, Factual</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Drug Industry</subject><subject>Drug prescriptions</subject><subject>Drug prices</subject><subject>Economic Competition</subject><subject>Economic Policy</subject><subject>FDA approval</subject><subject>Generic drugs</subject><subject>Health care expenditures</subject><subject>Health Care Management</subject><subject>Health Economics</subject><subject>Health insurance</subject><subject>Herfindahl Hirschman index</subject><subject>Hospital costs</subject><subject>Hospitals</subject><subject>Hospitals - classification</subject><subject>Hospitals - statistics & numerical data</subject><subject>Humans</subject><subject>International comparisons</subject><subject>Market prices</subject><subject>Market shares</subject><subject>Marketing of Health Services</subject><subject>Medical technology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>National health insurance</subject><subject>National Health Programs - statistics & numerical data</subject><subject>Nonprofit hospitals</subject><subject>Original Paper</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceutical preparations</subject><subject>Pharmaceutical Preparations - economics</subject><subject>Pharmaceuticals</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Prescription drugs</subject><subject>Price level changes</subject><subject>Public Finance</subject><subject>Public Health</subject><subject>Reimbursement</subject><subject>Studies</subject><subject>Taiwan</subject><subject>Technological change</subject><subject>Thiazolidinediones - economics</subject><subject>Thiazolidinediones - therapeutic use</subject><issn>1618-7598</issn><issn>1618-7601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kc1uFSEYhifGxtbqBbjQEDddTeVngMFd01g1aVIXdU0Y-KaH4xwYgbHR6_CCpZlTrS5cQeB5n4_wNs0Lgk8JxvJNJpiovsVYtZjIriWPmiMiSN9Kgcnj-z1X_WHzNOctxpRKyp40h0SJTgkhjpqfnzYm7YyFpXhrJjRDgJJM8TGgOKIAt8il5QaZ4ND8N7oz6QsUlEtabFkSIB_QtfG3JrxFm5hnX8zUTvANqjVBtsnP99qy8eZHnLzzAVw9g4zGmJDzZoAC-VlzMJopw_P9etx8vnh3ff6hvbx6__H87LK1HeeltY4zKkTfDcJS0bGhU8ZwwsGQTg2gFEjCR0HtODrXq5E6QQ12A4yD6QXD7Lg5Wb1zil8XyEXvfLYwTSZAXLKWjHHBGZGVfP0PuY1LCvVxmiimiBScVoiskE0x5wSjnpOvv_RdE6zvCtNrYboWpu8K06RmXu3Fy7AD9yexb6gCdAVyvQo3kB5M_o_15Rra5hLTb2mHJcNSUPYL1E6uXQ</recordid><startdate>20100601</startdate><enddate>20100601</enddate><creator>Tsai, Yi-Wen</creator><creator>Wen, Yu-Wen</creator><creator>Huang, Weng-Foung</creator><creator>Kuo, Ken N.</creator><creator>Chen, Pei-Fen</creator><creator>Shih, Hsin-Wei</creator><creator>Lee, Yue-Chune</creator><general>Springer</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100601</creationdate><title>Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes</title><author>Tsai, Yi-Wen ; Wen, Yu-Wen ; Huang, Weng-Foung ; Kuo, Ken N. ; Chen, Pei-Fen ; Shih, Hsin-Wei ; Lee, Yue-Chune</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-cd5326684b6c2643b49aa515ea149be99e715f62cffdd89f2d62a0dbefba86303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Bargaining</topic><topic>Brand names</topic><topic>Databases, Factual</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Drug Industry</topic><topic>Drug prescriptions</topic><topic>Drug prices</topic><topic>Economic Competition</topic><topic>Economic Policy</topic><topic>FDA approval</topic><topic>Generic drugs</topic><topic>Health care expenditures</topic><topic>Health Care Management</topic><topic>Health Economics</topic><topic>Health insurance</topic><topic>Herfindahl Hirschman index</topic><topic>Hospital costs</topic><topic>Hospitals</topic><topic>Hospitals - classification</topic><topic>Hospitals - statistics & numerical data</topic><topic>Humans</topic><topic>International comparisons</topic><topic>Market prices</topic><topic>Market shares</topic><topic>Marketing of Health Services</topic><topic>Medical technology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>National health insurance</topic><topic>National Health Programs - statistics & numerical data</topic><topic>Nonprofit hospitals</topic><topic>Original Paper</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceutical preparations</topic><topic>Pharmaceutical Preparations - economics</topic><topic>Pharmaceuticals</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Prescription drugs</topic><topic>Price level changes</topic><topic>Public Finance</topic><topic>Public Health</topic><topic>Reimbursement</topic><topic>Studies</topic><topic>Taiwan</topic><topic>Technological change</topic><topic>Thiazolidinediones - economics</topic><topic>Thiazolidinediones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsai, Yi-Wen</creatorcontrib><creatorcontrib>Wen, Yu-Wen</creatorcontrib><creatorcontrib>Huang, Weng-Foung</creatorcontrib><creatorcontrib>Kuo, Ken N.</creatorcontrib><creatorcontrib>Chen, Pei-Fen</creatorcontrib><creatorcontrib>Shih, Hsin-Wei</creatorcontrib><creatorcontrib>Lee, Yue-Chune</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsai, Yi-Wen</au><au>Wen, Yu-Wen</au><au>Huang, Weng-Foung</au><au>Kuo, Ken N.</au><au>Chen, Pei-Fen</au><au>Shih, Hsin-Wei</au><au>Lee, Yue-Chune</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes</atitle><jtitle>The European journal of health economics</jtitle><stitle>Eur J Health Econ</stitle><addtitle>Eur J Health Econ</addtitle><date>2010-06-01</date><risdate>2010</risdate><volume>11</volume><issue>3</issue><spage>279</spage><epage>290</epage><pages>279-290</pages><issn>1618-7598</issn><eissn>1618-7601</eissn><abstract>This study used Taiwan's National Health Insurance claim database (years 2000-2005) to examine how thiazolidinediones (TZD), a new class of drugs for diabetes, penetrated into Taiwan's hospitals, and its association with the concentration of all diabetes drugs at the hospital level. We collected 72 monthly summaries of diabetes prescriptions from all hospitals in Taiwan. Hospitallevel pharmaceutical concentration was measured by penetration of TZD, defined as monthly market share of TZD in each hospital. Concentration of diabetes drugs was measured by Herfindahl-Hirschman indices. We found a negative association (coefficient = — 0.3610) between TZD penetration and concentration of diabetes drug but a positive association between penetration of TZD and the volume of prescribed diabetes drugs (coefficient = 0.4088). In conclusion, hospital characteristics and volume of services determined the concentration of Pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of new drugs.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer</pub><pmid>19649666</pmid><doi>10.1007/s10198-009-0174-1</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1618-7598 |
| ispartof | The European journal of health economics, 2010-06, Vol.11 (3), p.279-290 |
| issn | 1618-7598 1618-7601 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733565317 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; SpringerLink Journals - AutoHoldings |
| subjects | Bargaining Brand names Databases, Factual Diabetes Diabetes Mellitus - drug therapy Drug Industry Drug prescriptions Drug prices Economic Competition Economic Policy FDA approval Generic drugs Health care expenditures Health Care Management Health Economics Health insurance Herfindahl Hirschman index Hospital costs Hospitals Hospitals - classification Hospitals - statistics & numerical data Humans International comparisons Market prices Market shares Marketing of Health Services Medical technology Medicine Medicine & Public Health National health insurance National Health Programs - statistics & numerical data Nonprofit hospitals Original Paper Pharmaceutical industry Pharmaceutical preparations Pharmaceutical Preparations - economics Pharmaceuticals Pharmacoeconomics and Health Outcomes Practice Patterns, Physicians' - statistics & numerical data Prescription drugs Price level changes Public Finance Public Health Reimbursement Studies Taiwan Technological change Thiazolidinediones - economics Thiazolidinediones - therapeutic use |
| title | Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A26%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmaceutical%20penetration%20of%20new%20drug%20and%20pharmaceutical%20market%20structure%20in%20Taiwan:%20hospital-level%20prescription%20of%20thiazolidinediones%20for%20diabetes&rft.jtitle=The%20European%20journal%20of%20health%20economics&rft.au=Tsai,%20Yi-Wen&rft.date=2010-06-01&rft.volume=11&rft.issue=3&rft.spage=279&rft.epage=290&rft.pages=279-290&rft.issn=1618-7598&rft.eissn=1618-7601&rft_id=info:doi/10.1007/s10198-009-0174-1&rft_dat=%3Cjstor_proqu%3E40730762%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=193917652&rft_id=info:pmid/19649666&rft_jstor_id=40730762&rfr_iscdi=true |